Flu vaccines are updated every year, but the 2026–27 season brings a notable change: an mRNA vaccine has joined the options available to some adults in the United States.
The vaccine, called MFLUSIVA, was developed by Moderna and is approved for adults aged 50 and older. Unlike traditional flu vaccines that use established approaches to present influenza proteins to the immune system, it uses messenger RNA, the same basic technology that made headlines during the COVID-19 pandemic.
Its arrival comes as scientists prepare for another unpredictable flu season. Influenza viruses constantly change, which means researchers have to decide months in advance which strains vaccines should target. For 2026–27, all three components of U.S. seasonal flu vaccines were updated, including a change aimed at the influenza A(H3N2) subclade K virus that circulated widely during the previous season.
So the question heading into the new season is not simply whether there is a new vaccine. It is whether this new technology can offer a meaningful advantage against a virus that keeps changing.
How the New mRNA Vaccine Works
Messenger RNA, or mRNA, carries temporary instructions that cells can use to make proteins.
An mRNA vaccine uses those instructions to prompt the body to produce a harmless piece of a virus. The immune system recognizes it as foreign and builds a response, preparing the body to respond more quickly if it encounters the actual virus.
That approach is different from many conventional flu vaccines, but the goal is familiar: train the immune system before influenza arrives.
MFLUSIVA was evaluated in a Phase 3 study involving more than 20,000 adults aged 50 and older. In the FDA's review, the vaccine showed a 26.6% relative vaccine efficacy compared with a standard-dose flu vaccine against laboratory-confirmed influenza illness caused by influenza A or B.
The result is encouraging, but it does not mean the mRNA vaccine is automatically the best choice for everyone.
For adults 65 and older, the evidence is more nuanced. The vaccine produced immune responses that supported its approval, but the FDA requires additional research to confirm clinical benefit in this older population.
That distinction is important because an immune response measured in a laboratory is not the same thing as proving that fewer people will actually get sick.
Why Flu Vaccines Change Every Year
Even a highly effective vaccine has to contend with influenza's ability to evolve.
The viruses circulating in one flu season can differ from those that dominated the previous year. Scientists therefore monitor influenza around the world and select vaccine strains that are expected to be most relevant when the next season begins.
The 2026–27 U.S. vaccines reflect that process. All three vaccine components were updated from the previous season, with particular attention to the H3N2 subclade K virus.
This is also why early flu activity in the Southern Hemisphere attracts attention in the months before winter arrives in North America. It can provide clues about which influenza viruses are circulating and how they are behaving, although it cannot reliably predict exactly how the Northern Hemisphere season will unfold.
The uncertainty is part of what makes influenza different from illnesses caused by a single, relatively stable virus.
When Should People Get The Flu Vaccine?
The arrival of a new vaccine does not change the basic timing of seasonal vaccination.
CDC guidance says annual influenza vaccination is recommended for people aged 6 months and older who do not have a contraindication. For most people who need one dose, vaccination is ideally offered in September or October.
The timing is deliberate. Immunity can weaken over the course of the flu season, so getting vaccinated too early may not always be preferable, particularly for some older adults.
Still, waiting indefinitely is not useful either. CDC guidance says vaccination should continue after October while influenza viruses are circulating and vaccines remain available.
For people aged 65 and older, the CDC preferentially recommends certain higher-dose or adjuvanted vaccines when available. MFLUSIVA's approval for adults aged 50 and older gives some people another option, but there is no blanket recommendation that the mRNA vaccine should replace other appropriate vaccines.
What This Could Mean For Future Flu Vaccines
The significance of an mRNA flu vaccine extends beyond this year's vaccination appointments.
Influenza has long presented a manufacturing challenge because vaccine strains have to be selected and produced ahead of the season. mRNA technology has attracted interest partly because its platform can be adapted to different targets.
But whether that translates into better protection in the real world still has to be demonstrated.
Flu vaccine effectiveness varies from season to season depending on the viruses circulating, how closely they match the vaccine, and characteristics of the people being vaccinated. CDC conducts effectiveness studies every season for precisely that reason.
For now, the new mRNA option is best viewed as another development in the long effort to keep seasonal influenza under control, rather than a breakthrough that settles the problem.
As the 2026–27 season approaches, surveillance will reveal whether the strains scientists anticipated are the ones that actually dominate. The answer may ultimately tell us as much about the future of flu vaccination as the arrival of the new technology itself.
